布西珠单抗治疗新生血管性年龄相关性黄斑变性后视网膜血管炎或血管阻塞:真实世界证据的系统综述
本系统综述检索真实世界实践文献,纳入19篇出版物,描述63例患者(70眼)在布西珠单抗注射后发生视网膜血管炎或血管阻塞(RV/RO)。平均年龄77.6岁,77.8%为女性;45.7%眼在首次注射后发生事件,平均19.4天,87.5%在30天内。有视力评估的眼中52.4%视力不变或改善,35.7%视力下降≥0.30 logMAR。
要点
- 真实世界报告中布西珠单抗后RV/RO事件多发生于女性(77.8%)。
- 45.7%眼在单次注射后发生事件,87.5%事件在末次注射后30天内。
- 有视力评估的眼中35.7%在最新随访时视力下降≥0.30 logMAR。
核心结论
- 早期真实世界实践中布西珠单抗后报告的RV/RO事件多数发生在女性。
- 在有视力测量的眼中约半数经历视力丧失;总体约三分之一在最新随访时视力下降≥0.30 logMAR,并提示存在区域差异。
研究设计与样本
- 系统文献综述,检索识别89篇出版物,最终纳入19篇。
- 描述了63例患者(70眼)在布西珠单抗后发生RV/RO事件。
主要发现
- 平均年龄77.6岁,77.8%的患者为女性;32眼(45.7%)在RV/RO前接受过一次布西珠单抗注射。
- 距末次布西珠单抗注射至事件的平均(范围)时间为19.4(0-63)天,87.5%的事件发生在30天内。
- 在有事件前和事件后视力评估的眼中,22/42眼(52.4%)在最新随访时视力较末次事件前记录不变(±0.08 logMAR)或改善;15/42眼(35.7%)视力下降≥0.30 logMAR(≥15个字母)。
- 无视力丧失的患者平均稍年轻,且非阻塞性事件比例更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Retinal vasculitis or vascular occlusion (RV/RO) have been reported after brolucizumab for neovascular age-related macular degeneration. This systematic literature review evaluated RV/RO events after brolucizumab in real-world practice. METHODS: Systematic literature searches identified 89 publications; 19 were included. RESULTS: Publications described 63 patients (70 eyes) with an RV/RO event following brolucizumab. Mean age was 77.6 years and 77.8% of patients were women; 32 eyes (45.7%) received one brolucizumab injection before RV/RO. Mean (range) time to event from last brolucizumab injection was 19.4 (0-63) days, with 87.5% of events occurring within 30 days. Among eyes with preevent and postevent visual acuity (VA) assessments, 22/42 eyes (52.4%) showed unchanged (±0.08 logMAR) or improved vision from last recorded preevent assessment at latest follow-up, whereas 15/42 eyes (35.7%) showed ≥0.30 logMAR (≥15 letters) VA reduction. Patients with no VA loss were on average slightly younger and had a higher proportion of nonocclusive events. CONCLUSION: Most RV/RO events reported after brolucizumab in early real-world practice occurred in women. Among eyes with VA measurements, approximately half experienced VA loss; overall, about one-third had VA reduction of ≥0.30 logMAR at latest follow-up, with indications of regional variations.
引用
- Wykoff CC, Matsumoto H, Barakat MR, et al. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence. Retina. 2023. PMID: 36893438. doi:10.1097/IAE.0000000000003769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。